Entries by Thomas Gabrielczyk

Lesaffre invests €15.5m in phage start-up

French yeast manufacturer Lesaffre acquires an equity stake in US biotech company Intralytix. Paying more than €15m, Lesaffre gains valuable insights into the development and commercialisation of bacteriophage-based products.

€7.6m by CARB-X dangling for Antabio

French Antabio receives funding by the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). Including future milestone payments, Antabio is eligible for up to €7.6m for their treatment of chronic infections in cystic fibrosis patients.

Ablynx adds Sanofi to its list of pharma partners

Belgian nanobody-developer Ablynx NV now also works together with French pharma company Sanofi. The deal is potentially worth €2.4bn but comes with an upfront payment of just €23m. The partners will initially focus on therapeutics for the treatment of various immune-mediated inflammatory diseases.

UK invests £86m in healthcare SMEs

The UK government has set up a new fund to support medical innovation. Breakthrough innovations that have the potential to benefit the NHS will also undergo accelerated access review aimed at speeding up access to novel medicines. 

German PEI limits use of daclizumab

Following a safety warning of the EMA on deaths related to Biogen’s multiple scleroisis (MS) drug Zinbryta (daclizumab), German regulatory authority has issued a red hand letter.